Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Emerging drug treatments for solid tumours

J H Schellens¹, L C Pronk, J Verweij

¹Department of Medical Oncology, Rotterdam Cancer Institute/Daniel den Hoed Kliniek, Rotterdam, The Netherlands.

|January 1, 1996

Summary

Novel anticancer agents targeting specific molecular pathways show promise against resistant solid tumors. These new therapies aim to improve treatment response, survival rates, and palliative care for advanced cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations.

Journal of clinical pharmacy and therapeutics·2018

Same author

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Oncotarget·2017

Same author

Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer.

Critical reviews in oncology/hematology·2015

Same author

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

Annals of oncology : official journal of the European Society for Medical Oncology·2014

Same author

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.

British journal of cancer·2012

Same author

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2010

Area of Science:

Oncology
Pharmacology

Background:

Recent decades have seen the emergence of novel anticancer agents with significant preclinical and early clinical activity.
These agents often possess unique mechanisms of action, demonstrating efficacy against various malignancies, including drug-resistant tumors.

Purpose of the Study:

To review emerging drug therapies and treatment modalities in oncology.
To highlight novel anticancer agents targeting specific molecular pathways and discuss advances in understanding and modulating drug toxicity.

Main Methods:

Review of novel anticancer agents and their mechanisms of action.
Discussion of molecular targets such as the mitotic tubulin/microtubuli system, nuclear enzymes, and cell signal transduction pathways.
Examination of advances in understanding and managing drug toxicity, exemplified by cisplatin and amifostine (WR-2721).

Main Results:

Novel agents show high activity in preclinical models and promising results in early patient trials for solid tumors.
Development of targeted therapies based on increased understanding of cancer's molecular basis.
Progress in understanding and modulating drug toxicity, leading to agents like amifostine.

Conclusions:

Emerging drug therapies and novel anticancer agents offer hope for improved outcomes in advanced cancer.
These advancements are expected to increase response rates, prolong disease-free and overall survival, and enhance palliative care.

Related Experiment Videos